Biosimilars

Biosimilars May Lead to Improved Competition and Lower Costs

September 11, 2020

How will biosimilars continue to affect the prescription product market in 2021?

Study Compares Cost, Accessibility of Novel Cancer Drugs in US and India

August 07, 2020

The advent of generic and biosimilar medicines for novel treatments has helped bridge the gap in the delivery of cancer care between the United States and India, according to the study.

Studies Reveal Positive Results for Infliximab Biosimilar

June 18, 2020

In studies presented this month at the European E-Congress of Rheumatology 2020, investigators revealed positive findings for the infliximab biosimilar CT-P13 (Inflectra, Remsima), which is developed by Celltrion of Incheon, Republic of Korea.

Rituximab Biosimilar Now Available in United States for Rheumatoid Arthritis

May 04, 2020

Rituximab-abbs (Truxima) is the only biosimilar to the reference product rituximab (Rituxan). 

Merck Announces US Launch of Trastuzumab Biosimilar

April 15, 2020

Merck has announced the US launch of trastuzumab-dttb (Ontruzant), a biosimilar to trastuzumab (Herceptin), in both 150-mg single-dose vials and 420-mg multiple-dose vials.

FDA Approves 420-mg Multi-Dose Vial of Trastuzumab Biosimilar

March 24, 2020

Officials with the FDA have approved a 420-mg multi-dose of trastuzumab-bttb (Ontruzant, Samsung Bioepis), a biosimilar referencing trastuzumab (Herceptin).

Pfizer Announces US Launch of 3 New Oncology Biosimilars

January 23, 2020

Pfizer announced the introduction of 3 new oncology biosimilars to the US market at a substantially discounted price.

FDA Approves Amgen’s Infliximab-axxq

December 06, 2019

Biosimilar to Remicade

Pfizer Gains FDA Approval for Humira Biosimilar

November 18, 2019

Expected U.S. launch in 2023.

Biosimilars: Some Call for ‘Cautious Optimism’

October 01, 2019

Biosimilars may need more time to devleop in the market.

Biosimilars Need Access and Cost Examinations

September 27, 2019

Biologic medicines could lower spending by $153 billion by 2023.

Generics and Biosimilars Facing Formulary Difficulties

September 11, 2019

New changes are making it more difficult for generics and biosimilars to compete on formularies.

FDA Approves Ruxience, a Rituxan Biosimilar

July 23, 2019

CD20-directed antibody indicated for several cancers and other conditions.

FDA Finalizes Guidance on Interchangeability for Biologics

May 10, 2019

Biosimilar guidance provides “clarity” for drug developers.

Trazimera, Herceptin Biosimilar, Gains FDA Approval

March 12, 2019

Indicated for breast cancer, and gastric or gastroesophageal junction adenocarcinoma. 

Biosimilar Naming Change Eliminates Potentially High Consumer Costs

March 08, 2019

Only new biosimilars and interchangeables will recieve four-letter suffixes.

Better Management Strategies Needed, Suggests Ninth Annual Medical Pharmacy Trend

February 19, 2019

The report by Magellan Rx Management indicates PMPM, site of service, and Medicaid prices continue to increase. 

Specialty Pharma to be Half of Total Drug Spend in a Few Years

December 13, 2018

Specialty pharmaceuticals make up a significant part of the current drug market, and their impact is only going to grow over the next few years.

The Push Is on for Generics and Biosimilars

September 03, 2018

Stalled competition hurts consumers and may keep prices higher.

What the FDA Wants Pharmacists to Know About Generic Drugs

August 24, 2018

Drug Topics recently spoke with the FDA about the role pharmacists can play in patient education.